Copeptin and Long-Term Risk of Recurrent Vascular Events after Transient Ischemic Attack and Ischemic Stroke: Population-Based Study

Stroke

Volumn 46, Issue 11, 2015, Pages 3117-3123

  Greisenegger, Stefan ^a,b   Segal, Helen C ^a   Burgess, Annette I ^a   Poole, Debbie L ^a   Mehta, Ziyah ^a   Rothwell, Peter M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

biomarkers; risk; stroke

Indexed keywords

COPEPTIN; BIOLOGICAL MARKER; GLYCOPEPTIDE;

AGE; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CARDIOVASCULAR MORTALITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; BLOOD; HEALTH SURVEY; ISCHEMIC ATTACK, TRANSIENT; PROCEDURES; STROKE; TIME FACTOR; VASCULAR DISEASES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; BRAIN ISCHEMIA; FEMALE; GLYCOPEPTIDES; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; POPULATION SURVEILLANCE; RECURRENCE; RISK FACTORS; STROKE; TIME FACTORS; VASCULAR DISEASES;

EID: 84945973306     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011021     Document Type: Article

References (33)

1. Lloyd-Jones DM, Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 2010 121 1768 1777. doi: 10.1161/CIRCULATIONAHA.109.849166
2. Jacobs DR Jr, Kroenke C, Crow R, Deshpande M, Gu DF, Gatewood L, PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation 1999 100 599 607
3. Choudhary R, Iqbal N, Khusro F, Higginbotham E, Green E, Maisel A, Heart failure biomarkers. J Cardiovasc Transl Res 2013 6 471 484. doi: 10.1007/s12265-013-9465-0
4. Battistoni A, Rubattu S, Volpe M, Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol 2012 157 160 168. doi: 10.1016/j.ijcard.2011.06.066
5. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007 115 2103 2110. doi: 10.1161/CIRCULATIONAHA.106.685503
6. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, OPTIMAAL Investigators C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009 30 1187 1194. doi: 10.1093/eurheartj/ehp098
7. Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler NG, Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006 36 771 778. doi: 10.1111/j.1365-2362.2006.01724.x
8. Neuhold S, Huelsmann M, Strunk G, Struck J, Adlbrecht C, Gouya G, Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem 2010 56 121 126. doi: 10.1373/clinchem.2009.125856
9. Katan M, Nigro N, Fluri F, Schuetz P, Morgenthaler NG, Jax F, Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011 76 563 566. doi: 10.1212/WNL.0b013e31820b75e6
10. De Marchis GM, Weck A, Audebert H, Benik S, Foerch C, Buhl D, Copeptin for the prediction of recurrent cerebrovascular events after transient ischemic attack: results from the CoRisk study. Stroke 2014 45 2918 2923. doi: 10.1161/STROKEAHA.114.005584
11. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009 66 799 808. doi: 10.1002/ana.21783
12. De Marchis GM, Katan M, Weck A, Fluri F, Foerch C, Findling O, Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology 2013 80 1278 1286. doi: 10.1212/WNL.0b013e3182887944
13. Urwyler SA, Schuetz P, Fluri F, Morgenthaler NG, Zweifel C, Bergmann A, Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 2010 41 1564 1567. doi: 10.1161/STROKEAHA.110.584649
14. Zhang JL, Yin CH, Zhang Y, Zhao LB, Fu HJ, Feng JC, Plasma copeptin and long-term outcomes in acute ischemic stroke. Acta Neurol Scand 2013 128 372 380. doi: 10.1111/ane.12132
15. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Oxford Vascular Study Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004 363 1925 1933. doi: 10.1016/S0140-6736(04)16405-2
16. Hatano S, Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976 54 541 553
17. Coull AJ, Silver LE, Bull LM, Giles MF, Rothwell PM, Oxford Vascular (OXVASC) Study Direct assessment of completeness of ascertainment in a stroke incidence study. Stroke 2004 35 2041 2045. doi: 10.1161/01.STR.0000137605.48864.2f
18. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009 119 2408 2416. doi: 10.1161/CIRCULATIONAHA.109.192278
19. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statist Med 2007 27 157 172. doi: 10.1002/sim.2929
20. Pencina MJ, D'Agostino RB, Vasan RS, Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010 48 1703 1711
21. Pencina MJ, D'Agostino RB Sr, Demler OV, Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. Stat Med 2012 31 101 113. doi: 10.1002/sim.4348
22. Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Müller B, Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 2007 92 2640 2643. doi: 10.1210/jc.2006-2046
23. Yalta K, Yalta T, Sivri N, Yetkin E, Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013 167 1750 1759. doi: 10.1016/j.ijcard.2012.12.039
24. Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 2008 14 739 745. doi: 10.1016/j.cardfail.2008.07.231
25. Katan M, Morgenthaler N, Widmer I, Puder JJ, König C, Müller B, Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008 29 341 346
26. Katan M, Christ-Crain M, The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010 140 w13101. doi: 10.4414/smw.2010.13101
27. Enhörning S, Struck J, Wirfält E, Hedblad B, Morgenthaler NG, Melander O, Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 2011 96 E1065 E1072. doi: 10.1210/jc.2010-2981
28. Tenderenda-Banasiuk E, Wasilewska A, Filonowicz R, Jakubowska U, Waszkiewicz-Stojda M, Serum copeptin levels in adolescents with primary hypertension. Pediatr Nephrol 2014 29 423 429. doi: 10.1007/s00467-013-2683-5
29. Silver LE, Segal H, Syed A, Mehta Z, Rothwell PM, Long-term prognostic value of aspirin non-responsiveness and platelet reactivity after acute vascular events: a population-based prospective cohort study. Cerebrovasc Dis 2009 27 suppl 5 I XXVII
30. Segal HC, Burgess AI, Poole DL, Mehta Z, Silver LE, Rothwell PM, Population-based study of blood biomarkers in prediction of subacute recurrent stroke. Stroke 2014 45 2912 2917. doi: 10.1161/STROKEAHA.114.005592
31. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, Early use of Existing Preventive Strategies for Stroke (EXPRESS) Study Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007 370 1432 1442. doi: 10.1016/S0140-6736(07)61448-2
32. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008 52 266 272. doi: 10.1016/j.jacc.2008.03.050
33. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007 13 42 49. doi: 10.1016/j.cardfail.2006.09.004